Lipocine
LPCN
42 hedge funds and large institutions have $21.9M invested in Lipocine in 2017 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 11 increasing their positions, 12 reducing their positions, and 20 closing their positions.
74% more call options, than puts
Call options by funds: $1.4M | Put options by funds: $801K
0.68% less ownership
Funds ownership: 2.34% → 1.67% (-0.68%)
8% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 12
16% less funds holding
Funds holding: 50 → 42 (-8)
24% less capital invested
Capital invested by funds: $28.9M → $21.9M (-$6.96M)
40% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DAM
DLD Asset Management
New York
|
+$698K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$595K |
| 3 |
Millennium Management
New York
|
+$355K |
| 4 |
ECM
Element Capital Management
New York
|
+$310K |
| 5 |
Goldman Sachs
New York
|
+$286K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$4.15M |
| 2 |
BlackRock
New York
|
-$2.63M |
| 3 |
State Street
Boston,
Massachusetts
|
-$859K |
| 4 |
JP Morgan Chase
New York
|
-$755K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$559K |
LPCN Hedge Fund Activity: Q2 2017 in Review
42 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q2 2017, worth a combined $21.9M — down 24% from $28.9M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of LPCN and 12 opened new positions — a net loss of 8 holders — while 12 trimmed existing stakes and 11 added.
The largest buyer was DLD Asset Management, opening a new position worth an estimated $698K. The largest seller was Invesco, exiting entirely with an estimated $4.15M sold.
- 42 institutional investors held Lipocine (LPCN) as of Q2 2017, down from 50 in Q1 2017.
- Funds reported $21.9M of Lipocine stock for Q2 2017, down 24% quarter-over-quarter.
- 12 funds opened new Lipocine positions in Q2 2017 and 20 closed out, a net change of -8 holders.
- The largest Lipocine buyer in Q2 2017 was DLD Asset Management, an estimated $698K added.
- The largest Lipocine seller in Q2 2017 was Invesco, an estimated $4.15M sold.
Based on aggregated 13F filings for Q2 2017.